Sienna Biopharmaceuticals Stock Price, News & Analysis (NASDAQ:SNNA)

$15.98 -0.14 (-0.87 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$15.98
Today's Range$15.51 - $16.21
52-Week Range$13.37 - $29.25
Volume65,928 shs
Average Volume64,164 shs
Market Capitalization$331.09 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Sienna Biopharmaceuticals (NASDAQ:SNNA)

Sienna Biopharmaceuticals, Inc. is a United States-based medical dermatology and aesthetics company. The Company focuses on developing targeted therapies to treat inflammatory skin conditions and aesthetic concerns that impact the health and appearance of patients. Its research and clinical-stage candidates include programs, such as SNA-001, SNA-120 and SNA-125. The Company has developed over 70 products. Its SNA-120 and SNA-125 are generated through its Topical by Design platform technology. Its SNA-120 is a Topical Tropomyosin Receptor Kinase A (TrkA) inhibitor for pruritus and psoriasis. Its SNA-125 is a Topical TrkA/Janus Kinase 3 (JAK3) Inhibitor for atopic dermatitis, psoriasis and pruritus. Its SNA-001 is a Topical Photoparticle Therapy for medical and aesthetic applications. Its SNA-001 Topical Photoparticle Therapy is used for localized and non-systemic treatment of acne. Its SNA-001 Topical Photoparticle Therapy is used for reduction of light-pigmented hair.

Receive SNNA News and Ratings via Email

Sign-up to receive the latest news and ratings for SNNA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SNNA
CUSIPN/A
Phone818-629-2256

Debt

Debt-to-Equity RatioN/A
Current Ratio6.72%
Quick Ratio6.72%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees43
Outstanding Shares20,540,000

Sienna Biopharmaceuticals (NASDAQ:SNNA) Frequently Asked Questions

What is Sienna Biopharmaceuticals' stock symbol?

Sienna Biopharmaceuticals trades on the NASDAQ under the ticker symbol "SNNA."

How were Sienna Biopharmaceuticals' earnings last quarter?

Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) announced its quarterly earnings results on Thursday, September, 7th. The company reported ($6.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by $5.82. View Sienna Biopharmaceuticals' Earnings History.

Where is Sienna Biopharmaceuticals' stock going? Where will Sienna Biopharmaceuticals' stock price be in 2018?

4 analysts have issued 1-year price targets for Sienna Biopharmaceuticals' stock. Their predictions range from $21.00 to $50.00. On average, they expect Sienna Biopharmaceuticals' share price to reach $32.25 in the next twelve months. View Analyst Ratings for Sienna Biopharmaceuticals.

Who are some of Sienna Biopharmaceuticals' key competitors?

Who are Sienna Biopharmaceuticals' key executives?

Sienna Biopharmaceuticals' management team includes the folowing people:

  • Frederick C. Beddingfield III, M.D., Ph.D., President, Chief Executive Officer, Director (Age 51)
  • Richard D. Peterson, Chief Financial Officer (Age 49)
  • Majed Kheir, Vice President - Operations
  • Susan Lundeen, Vice President - Human Resources
  • Robert More, Director

When did Sienna Biopharmaceuticals IPO?

(SNNA) raised $64 million in an initial public offering (IPO) on Thursday, July 27th 2017. The company issued 4,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and BMO Capital Markets served as the underwriters for the IPO.

When did the company's lock-up period expire?

Sienna Biopharmaceuticals' lock-up period expired on Tuesday, January 23rd. Sienna Biopharmaceuticals had issued 4,333,333 shares in its IPO on July 27th. The total size of the offering was $64,999,995 based on an initial share price of $15.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the expiration of the lock-up period.

Who owns Sienna Biopharmaceuticals stock?

Sienna Biopharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (2.46%), Victory Capital Management Inc. (2.34%), TimesSquare Capital Management LLC (1.80%), Geode Capital Management LLC (0.22%), Deutsche Bank AG (0.06%) and Goldman Sachs Group Inc. (0.05%). Company insiders that own Sienna Biopharmaceuticals stock include Dennis M Fenton, Keith R Leonard, Paul F Lizzul, Richard D Peterson and Timothy K Andrews. View Institutional Ownership Trends for Sienna Biopharmaceuticals.

Who sold Sienna Biopharmaceuticals stock? Who is selling Sienna Biopharmaceuticals stock?

Sienna Biopharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including TimesSquare Capital Management LLC. View Insider Buying and Selling for Sienna Biopharmaceuticals.

Who bought Sienna Biopharmaceuticals stock? Who is buying Sienna Biopharmaceuticals stock?

Sienna Biopharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Victory Capital Management Inc., Goldman Sachs Group Inc., Deutsche Bank AG and Geode Capital Management LLC. Company insiders that have bought Sienna Biopharmaceuticals stock in the last two years include Dennis M Fenton, Keith R Leonard, Paul F Lizzul, Richard D Peterson and Timothy K Andrews. View Insider Buying and Selling for Sienna Biopharmaceuticals.

How do I buy Sienna Biopharmaceuticals stock?

Shares of Sienna Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sienna Biopharmaceuticals' stock price today?

One share of Sienna Biopharmaceuticals stock can currently be purchased for approximately $15.98.

How big of a company is Sienna Biopharmaceuticals?

Sienna Biopharmaceuticals has a market capitalization of $331.09 million. Sienna Biopharmaceuticals employs 43 workers across the globe.

How can I contact Sienna Biopharmaceuticals?

Sienna Biopharmaceuticals' mailing address is 30699 Russell Ranch Road Suite 140, Westlake Village CA, 91362. The company can be reached via phone at 818-629-2256 or via email at [email protected]


MarketBeat Community Rating for Sienna Biopharmaceuticals (SNNA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  64 (Vote Outperform)
Underperform Votes:  68 (Vote Underperform)
Total Votes:  132
MarketBeat's community ratings are surveys of what our community members think about Sienna Biopharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Sienna Biopharmaceuticals (NASDAQ:SNNA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.753.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $32.25$32.25$36.00$36.00
Price Target Upside: 57.09% upside57.09% upside85.76% upside85.76% upside

Sienna Biopharmaceuticals (NASDAQ:SNNA) Consensus Price Target History

Price Target History for Sienna Biopharmaceuticals (NASDAQ:SNNA)

Sienna Biopharmaceuticals (NASDAQ:SNNA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/5/2017GuggenheimInitiated CoverageNeutral -> Neutral$21.00LowView Rating Details
8/21/2017CowenInitiated CoverageOutperform$50.00HighView Rating Details
8/21/2017JPMorgan Chase & Co.Initiated CoverageOverweight -> Overweight$28.00HighView Rating Details
8/21/2017BMO Capital MarketsInitiated CoverageOutperform$30.00HighView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Sienna Biopharmaceuticals (NASDAQ:SNNA) Earnings History and Estimates Chart

Earnings by Quarter for Sienna Biopharmaceuticals (NASDAQ:SNNA)

Sienna Biopharmaceuticals (NASDAQ SNNA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($1.12)ViewN/AView Earnings Details
9/7/2017Q2 2017($0.68)($6.50)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Sienna Biopharmaceuticals (NASDAQ:SNNA) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.3 EPS
Next Year EPS Consensus Estimate: $-2.58 EPS

Dividends

Dividend History for Sienna Biopharmaceuticals (NASDAQ:SNNA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Sienna Biopharmaceuticals (NASDAQ SNNA) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 40.71%
Insider Trades by Quarter for Sienna Biopharmaceuticals (NASDAQ:SNNA)
Insider Trades by Quarter for Sienna Biopharmaceuticals (NASDAQ:SNNA)

Sienna Biopharmaceuticals (NASDAQ SNNA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/18/2017Dennis M FentonDirectorBuy1,250$22.96$28,700.001,250View SEC Filing  
8/1/2017Keith R LeonardDirectorBuy16,700$15.00$250,500.00View SEC Filing  
8/1/2017Paul F LizzulInsiderBuy10,000$15.00$150,000.0094,634View SEC Filing  
8/1/2017Richard D PetersonCFOBuy7,000$15.00$105,000.007,000View SEC Filing  
8/1/2017Timothy K AndrewsGeneral CounselBuy15,000$15.00$225,000.0051,737View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Sienna Biopharmaceuticals (NASDAQ SNNA) News Headlines

Source:
DateHeadline
Sienna Biopharmaceuticals Announces First Patient Dosed in First-in-Human Trial of Topical SNA-125Sienna Biopharmaceuticals Announces First Patient Dosed in First-in-Human Trial of Topical SNA-125
finance.yahoo.com - February 14 at 4:40 PM
Sienna Biopharmaceuticals (SNNA) Lifted to "Sell" at ValuEngineSienna Biopharmaceuticals (SNNA) Lifted to "Sell" at ValuEngine
www.americanbankingnews.com - February 4 at 1:16 PM
Sienna Biopharmaceuticals Incs (SNNA) Lock-Up Period To End  on January 23rdSienna Biopharmaceuticals Inc's (SNNA) Lock-Up Period To End on January 23rd
www.americanbankingnews.com - January 16 at 1:14 AM
Sienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare ConferenceSienna Biopharmaceuticals to Present at BMO Capital Markets Healthcare Conference
finance.yahoo.com - December 11 at 9:37 AM
The 10 Best New Stocks of 2017The 10 Best New Stocks of 2017
finance.yahoo.com - December 6 at 9:05 AM
Sienna Biopharmaceuticals (SNNA) Earns Neutral Rating from Analysts at GuggenheimSienna Biopharmaceuticals (SNNA) Earns Neutral Rating from Analysts at Guggenheim
www.americanbankingnews.com - December 5 at 8:48 PM
Sienna Biopharmaceuticals Reports Third Quarter 2017 Financial ResultsSienna Biopharmaceuticals Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 1:45 PM
Sienna Biopharmaceuticals (SNNA) Announces First Patient Dosed in Phase 2b Trial of Topical SNA-120Sienna Biopharmaceuticals (SNNA) Announces First Patient Dosed in Phase 2b Trial of Topical SNA-120
www.streetinsider.com - October 25 at 10:53 AM
Sienna Biopharmaceuticals Announces First Patient Dosed in Phase 2b Trial of Topical SNA-120Sienna Biopharmaceuticals Announces First Patient Dosed in Phase 2b Trial of Topical SNA-120
finance.yahoo.com - October 24 at 10:12 AM
SIENNA BIOPHARM (SNNA) Director Dennis M. Fenton Purchases 1,250 SharesSIENNA BIOPHARM (SNNA) Director Dennis M. Fenton Purchases 1,250 Shares
www.americanbankingnews.com - September 19 at 4:28 PM
SIENNA BIOPHARM (SNNA) Releases Quarterly  Earnings Results, Misses Expectations By $5.82 EPSSIENNA BIOPHARM (SNNA) Releases Quarterly Earnings Results, Misses Expectations By $5.82 EPS
www.americanbankingnews.com - September 8 at 9:29 AM
Sienna Biopharmaceuticals Reports Second Quarter 2017 Financial ResultsSienna Biopharmaceuticals Reports Second Quarter 2017 Financial Results
finance.yahoo.com - September 7 at 9:14 AM
Sienna Biopharms (SNNA) Quiet Period Will End  on September 5thSienna Biopharm's (SNNA) Quiet Period Will End on September 5th
www.americanbankingnews.com - September 2 at 1:22 AM
Sienna Biopharm (SNNA) Coverage Initiated at Cowen and CompanySienna Biopharm (SNNA) Coverage Initiated at Cowen and Company
www.americanbankingnews.com - August 21 at 8:52 AM
Sienna Biopharm (SNNA) Receives New Coverage from Analysts at J P Morgan Chase & CoSienna Biopharm (SNNA) Receives New Coverage from Analysts at J P Morgan Chase & Co
www.americanbankingnews.com - August 21 at 8:36 AM
Sienna Biopharm (SNNA) Now Covered by Analysts at BMO Capital MarketsSienna Biopharm (SNNA) Now Covered by Analysts at BMO Capital Markets
www.americanbankingnews.com - August 21 at 8:08 AM
Sienna Biopharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesSienna Biopharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - August 2 at 3:26 PM
Sienna Biopharmaceuticals Inc (SNNA) General Counsel Buys $225,000.00 in StockSienna Biopharmaceuticals Inc (SNNA) General Counsel Buys $225,000.00 in Stock
www.americanbankingnews.com - August 1 at 10:14 PM
Paul F. Lizzul Buys 10,000 Shares of Sienna Biopharmaceuticals Inc (SNNA) StockPaul F. Lizzul Buys 10,000 Shares of Sienna Biopharmaceuticals Inc (SNNA) Stock
www.americanbankingnews.com - August 1 at 7:50 PM
Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) CFO Acquires $105,000.00 in StockSienna Biopharmaceuticals Inc (NASDAQ:SNNA) CFO Acquires $105,000.00 in Stock
www.americanbankingnews.com - August 1 at 7:50 PM
Sienna Biopharmaceuticals Inc (SNNA) Director Keith R. Leonard Acquires 16,700 SharesSienna Biopharmaceuticals Inc (SNNA) Director Keith R. Leonard Acquires 16,700 Shares
www.americanbankingnews.com - August 1 at 7:48 PM
Sienna Biopharmaceuticals Prices IPO at $14.00-$16.00 Per Share (NASDAQ:SNNA)Sienna Biopharmaceuticals Prices IPO at $14.00-$16.00 Per Share (NASDAQ:SNNA)
www.americanbankingnews.com - July 19 at 10:58 AM

SEC Filings

Sienna Biopharmaceuticals (NASDAQ:SNNA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Sienna Biopharmaceuticals (NASDAQ:SNNA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Sienna Biopharmaceuticals (NASDAQ SNNA) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.